Abstract: Connectivity is tested using different locations and contexts selected from different possible failure zones. The failure zones may include: client failure zones; Internet failure zones; and online service failure zones. The results relating to different connectivity tests performed using the different failure zones are correlated and analyzed in an attempt to determine a root cause of the connectivity issue. For example, the root cause may be determined to be a configuration problem of the client, a problem with the client's networking equipment, an ISP problem, an Internet backbone problem; a problem of the online service, and the like. Different contexts may also be used when performing the tests. These results may be compared to the other connectivity test results. The results from the tests may be provided to the client experiencing the problem. Aggregated test results may also be used to detect service wide issues and trigger an alert.

Abstract: The present invention relates in general to polymer-drug conjugates. In particular, the invention relates to polymer-drug conjugates wherein the conjugated drugs are selected from prostaglandins and substituted prostaglandins, to a method of delivering such prostaglandin drugs to a subject, to a sustained drug delivery system comprising the polymer-drug conjugates, to a method of preparing the polymer-drug conjugates, and to an implant comprising the polymer-drug conjugates. The polymer-drug conjugates may be useful for delivering prostaglandins and substituted prostaglandins for the treatment of glaucoma.

Abstract: The invention relates to a biodegradable polymer comprising a plurality of releasable bioactive moieties, the releasable bioactive moieties being pendant from and covalently bonded to the biodegradable polymer backbone, wherein the biodegradable polymer backbone is formed from monomeric units that are each coupled via a biodegradable moiety, and wherein the bioactive moieties are capable of being released at a rate equal to or faster than the rate of biodegradation of the polymer backbone.

Abstract: The invention relates to a biodegradable polymer comprising a plurality of releasable bioactive moieties, the releasable bioactive moieties being pendant from and covalently bonded to the biodegradable polymer backbone, wherein the biodegradable polymer backbone is formed from monomeric units that are each coupled via a biodegradable moiety, and wherein the bioactive moieties are capable of being released at a rate equal to or faster than the rate of biodegradation of the polymer backbone.

Abstract: The invention relates to a biodegradable polymer comprising a plurality of releasable bioactive moieties, the releasable bioactive moieties being pendant from and covalently bonded to the biodegradable polymer backbone, wherein the biodegradable polymer backbone is formed from monomeric units that are each coupled via a biodegradable moiety, and wherein the bioactive moieties are capable of being released at a rate equal to or faster than the rate of biodegradation of the polymer backbone.

Abstract: A polyolefin production system, comprising a polymerization reactor (such as a polyethylene loop slurry reactor) and a fractionation system that receives reactor effluent processed in a diluent/monomer recovery system for recycle to the reactor and to suppliers. A conduit diverts a portion of a reflux flow comprising monomer, such as ethylene, from within the fractionation system to the polymerization reactor, providing for less venting of monomer, such as ethylene, to the supplier. Accordingly, monomer yield is advantageously increased, as the monomer returned to the reactor displaces monomer feedstock to the reactor. The reflux flow may originate from a condensed overhead lights from a diluent recycle column disposed in the fractionation subsystem. The diluent recycle column may receive a stream comprising diluent and monomer as feed from the diluent/monomer recovery subsystem, and may receive the non-diverted portion of the reflux flow as reflux.

Abstract: A method for transferring polymer within a polymerization system, comprising continuously withdrawing the polymer from the reactor and conveying the polymer from a reactor to a flash chamber via a pressure differential between the reactor and the flash chamber. A method for transferring polymer within a polymerization system comprising conveying the polymer from a reactor to a flash chamber via a pressure differential between the reactor and the flash chamber and purging interstitial gases from the polymer prior to conveying the polymer from the sash chamber to a purge column. A method for transferring polymer within a polymerization system comprising conveying the polymer from a flash chamber directly to a purge column via a pressure differential between the flash chamber and the purge column.

Abstract: A manufacturing process for producing polyolefin, having a feed system, a reactor system including at least one polymerization reactor, a diluent/monomer recovery system, a fractionation system, and an extrusion/loadout system having an extruder. The manufacturing process is configured to consume less than 325 kilowatt-hours of electricity per metric ton of polyolefin produced.

Abstract: A method for transferring polymer within a polymerization system, comprising continuously withdrawing the polymer from the reactor and conveying the polymer from a reactor to a flash chamber via a pressure differential between the reactor and the flash chamber. A method for transferring polymer within a polymerization system comprising conveying the polymer from a reactor to a flash chamber via a pressure differential between the reactor and the flash chamber and purging interstitial gases from the polymer prior to conveying the polymer from the flash chamber to a purge column. A method for transferring polymer within a polymerization system comprising conveying the polymer from a flash chamber directly to a purge column via a pressure differential between the flash chamber and the purge column.

Abstract: A pharmaceutical composition for topical administration, including, as the pharmaceutically active component, at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent composition including at least two of water, a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.

Abstract: Polymer solids are maintained in an intermediate pressure zone for a desired polymer solids residence time and then transferred to a purge zone or other lower pressure zone. An increase in the polymer solids residence time in the intermediate pressure zone allows more diluent to flash or separate, thereby avoiding or reducing the need for a low pressure flash zone. A fluff chamber may be disposed between the intermediate pressure zone and a lower pressure zone. A transporter tank may be used to transport polymer solids after the intermediate pressure zones.

Abstract: A pharmaceutical product containing pamidronate and other diphosphonate solutions in an appropriate container, a pH of between 5 and 8 and without organic acid buffer or polyethylen glycol. The container may be treated glass or made of other appropriate material. Coated elastomeric stoppers are also included. A method of producing a pharmaceutical product comprising steps of making a suspension of pamadronic acid, adding sodium hydroxide, to form a solution adjusting the pH to between 5 and 8 and transferring the solution to a container.

Abstract: A stable injectable solution containing pamidronate and a method for preparing a therapeutic aqueous disodium pamidronate solution. The method comprises preparing a slurry of pamidronic acid in water, combining aqueous sodium hydroxide with the slurry in an amount about 2:1 molar ratio of sodium hydroxide to pamidronic acid to yield a solution of disodium pamidronate having visual clarity and a pH of about 6.5, and packaging the solution in sealed containers. A unit dosage form including the solution and a vial or ampule comprising the unit dosage form are also described.

Abstract: A stable injectable solution containing pamidronate and a method for preparing a therapeutic aqueous disodium pamidronate solution. The method comprises preparing a slurry of pamidronic acid in water, combining aqueous sodium hydroxide with the slurry in an amount about 2:1 molar ratio of sodium hydroxide to parnidronic acid to yield a solution of disodium pamidronate having visual clarity and a pH of about 6.5, and packaging the solution in sealed containers. A unit dosage form including the solution and a vial or ampule comprising the unit dosage form are also described.

Abstract: A stable injectable solution containing pamidronate and a method for preparing a therapeutic aqueous disodium pamidronate solution. The method comprises preparing a slurry of pamidronic acid in water, combining aqueous sodium hydroxide with the slurry in an amount about 2:1 molar ratio of sodium hydroxide to pamidronic acid to yield a solution of disodium pamidronate having visual clarity and a pH of about 6.5, and packaging the solution in sealed containers. A unit dosage form including the solution and a vial or ampule comprising the unit dosage form are also described.

Abstract: A motorcycle includes a steered wheel assembly wherein the steered wheel is mounted on a hub member which is rigidly secured to one end of a telescopically sprung fork assembly the other end of which is pivoted to the frame. A radius arm assembly is also pivoted to the frame and to the hub member. The pivotal connection between the fork assembly and the frame is adjustable to alternative frame-fixed positions to vary the steering characteristics of the motorcycle.